Biotech Stock News (SRPT) (BMRN) (PBMD) (ISR)

Sarepta Therapeutics (NASDAQ:SRPT) After the closing bell on May 19, 2015 shares of Sarepta Therapeutics were up as much as 38% in after-hours trading after the company reported that the FDA will allow the company to file a New Drug Application — NDA — for Eteplirsen. This drug Eteplirsen helps patients with Duchenne Muscular Dystrophy … Read more

Prima Biomed (PBMD) Stock Presenting A Great Opportunity

Prima Biomed Sp ADR (NASDAQ: PBMD) This post was originally posted at Warrior Trading News! Yesterday was nothing short of incredible for Prima Biomed in the market. The stock jumped by more than 300% following information released regarding it’s most recent clinical trial. Today, we’ll talk about the data that was released, how the market … Read more

Prima Biomed (PBMD) Stock Is Back Up | Will It Last?

Prima Biomed Sp ADR (NASDAQ: PBMD) Prima Biomed has had a great week in the market. After releasing overwhelmingly positive data from a recent study, the stock nearly quadrupled in value on Wednesday. Unfortunately however, it ran into a big correction yesterday; losing a big percentage of the gains. So, yesterday, I wrote a post … Read more

Opportunity Spotter | PBMD | MNKD | SRPT

There are a few stocks that we’re watching very closely at the moment that we believe will generate great opportunities in the coming days in the market. Those include Sarepta Therapeutics, Prima Biomed, and MannKind Corporation. We’ve also dug up a few events to watch as we move into next week that are likely to cause big movements in the market. Below, we’ll discuss the opportunities we see with PBMD, SRPT and MNKD; as well as chat about the events in the economic calendar that should be watched closely.

Prima Biomed (PBMD) Stock Presenting A Great Opportunity For MoreĀ Gains

Prima Biomed Sp ADR (NASDAQ: PBMD)

Read more

Prima Biomed (PBMD) Stock Continues To Climb | Can It Last?

Prima Biomed Sp ADR (NASDAQ: PBMD) Prima Biomed has been having a great time in the market over the past two days. After releasing data Tuesday morning from its Phase II ovarian cancer trial, the stock has grown exponentially. Today, we’ll talk about the data that’s been released, how the markets reacted, and what we … Read more